Navigation Links
Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:3/1/2011

s proprietary endothelial cell-based platform to prevent solid tumor growth, cancer recurrence and metastatic disease.

About Pervasis Pervasis Therapeutics, Inc. is a clinical stage company that is developing groundbreaking endothelial cell-based therapies designed to regulate the body's natural healing and repair processes in various critical therapeutic areas. The company has initially focused on developing therapies to improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stent placements, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs. The company's lead program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 clinical trials. Pervasis is also applying its endothelial cell-based platform technology to develop an oncology therapy focused on preventing solid tumor growth, cancer recurrence and metastatic disease, as well as products for inflammatory disease and orthopedic injury.

Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. For more information, please visit www.pervasistx.com.  

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

(1)  Dixon et al. DAC Study Group. Effect of dipyridamole plus aspirin on he
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
2. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
5. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
6. Mylan Receives Approval for Generic Version of Neurontin® Capsules
7. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
8. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
9. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
10. Delcath Systems Receives Refusal to File Letter From FDA
11. Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Germany , and ... , Exclusive global license from ... SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for ... be targeted by new test, indicate favorable prognosis for ... QIAGEN sees potential for developing companion diagnostics ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, ... provider of medication and supply management solutions and ... call Thursday, July 31, to discuss the Company,s ... Omnicell Second Quarter 2014 earnings conference call and ... PTWho:  , Randall Lipps, chairman, president and chief ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... 2011 Masimo (NASDAQ: ... of Health & Human Services (HHS) has added Critical ... as a national newborn screening standard.  In addition, the ... detection, published online in the Lancet (appearing ...
... or the "Company") (NASDAQ: UNIS ; ASX: UNS) ... to purchase an additional U.S. $500,000 in shares of the ... 30th. These purchases of Unilife shares will be part of ... $1.0 million in shares by September 30th. This ...
Cached Medicine Technology:U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 2U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 3U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 4U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 5U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 6U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 7U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 8U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 9U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 10Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011 2Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011 3
(Date:7/25/2014)... The Little Gym of Houston will ... July 27 at Discovery Green in downtown Houston. The ... Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire ... “We’re thrilled to be attending and performing at the ... owns the Sugarland-Missouri City location. “We believe in the ...
(Date:7/25/2014)... Art of Facial Surgery has recently stepped up to ... are looking for minor touch-ups to make them more photogenic. ... Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) and ... showed a surprising increase between 2012 and 2013. The ... increased by 7 percent and eyelid surgery increased by 6 ...
(Date:7/25/2014)... Port Washington, NY (PRWEB) July 25, 2014 ... to protecting the rights of consumers comments on a ... the widow of a smoker $23.6 billion in punitive ... which manufactures Kool brand cigarettes. The case is Cynthia ... in 2008 in the Florida First Circuit Court, Escambia ...
(Date:7/25/2014)... 25, 2014 Hastings and Hastings, ... attorney’s fees with regard to personal injury claims, announces ... wide range of legal services for those that have ... another individual or corporation. Free initial consultation services gives ... of a potential personal injury claim . It ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Babies seem ... suggests. By the time women are 34 weeks ... of their mother,s voice reciting a familiar nursery rhyme, ... predominant source of sensory stimulation in the developing fetus," ... University of Florida,s College of Nursing, said in a ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2
... withdrawal of seven lines of their products Cadbury Schweppes ... more products because of salmonella contamination. ,Cadbury, ... withdraw seven lines of chocolates last month after admitting ... ,Reports of further testing and possible withdrawal of ...
... patisseries, Choco Fudge has been adjudged the best cookie amidst ... panel consisted of eminent writers and fashion designers from Kolkata, ... of place at all ITC hotels across the country as ... contest in Kolkata, ITC Hotels aims to give a boost ...
... to a new study, contrast-enhanced sonography compared with sonography ... the assessment of blunt abdominal trauma.// ,Massimo Valentino, ... of our study was to prospectively compare the diagnostic ... detection of solid organ injuries in blunt abdominal trauma ...
... about subject as sex is, perhaps vying with each other ... well known - responsible //for many diseases, failed pregnancy, miscarriage, ... a host of problems, like ADHD in the child and ... woman’s memory and hormonal cycles. ,Women seem to be ...
... H5N1 strain of bird flu has been detected in remote ... country to be hit by bird flu. ,Although ... cases have gone unnoticed. Currently 14 of Nigeria's 36 states ... "We have identified it in three places in Taraba, one ...
... says ‘significant fluctuations in the first hour blood pressure ... ,According to this study patient mortality increases ... rooted to an impaired autoregulation of blood pressure. ... ischemic stroke symptoms of less than 24 hours. Blood ...
Cached Medicine News:Health News:New Tool Found to be Effective in Assessing Blunt Abdominal Trauma 2Health News:Fluctuating BP and Stroke Lowered Patient Survival Rate 2
Half Trial Frames with precision engineering and lightweight material....
The award-winning new Universal Trial Frame (UB4), the ergonomic refraction design from Oculus that's easier to use, easier to wear....
Half Eye Trial Frame - Child...
... Universal Trial Frame comes at a very attractive price. ,The ... Temple length 4 1/8" to 5 1/2" (98 to ... to 30, PD adjustable 24 to 40mm on each ... on each lens: left - 120 to 0 to 135 ...
Medicine Products: